NCT03846882 (RECTOPET) is a clinical trial in Rectal Cancer, sponsored by Region Västerbotten.

Who is sponsoring NCT03846882?

NCT03846882 is sponsored by Region Västerbotten.

What condition does NCT03846882 study?

NCT03846882 studies Rectal Cancer, Lymph Node Metastases.

Is NCT03846882 still recruiting?

NCT03846882 is currently status unknown. Last updated 20 February 2019.

Last reviewed 2019-02-20 · How we verify

NCT03846882: RECTOPET

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FDG - PET / MRI in Patients With Rectal Cancer

Status unknown Last updated 20 February 2019

What this trial tests

trial in Rectal Cancer in 100 participants. Status unknown.

Timeline

1 December 2015

Primary endpoint
31 December 2021

31 December 2023

Quick facts

Lead sponsor	Region Västerbotten
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 December 2015
Primary completion	31 December 2021
Estimated completion	31 December 2023
Sites	1 location across Sweden

Conditions studied

Rectal Cancer — all drugs for Rectal Cancer →
Lymph Node Metastases — all drugs for Lymph Node Metastases →

Sponsor

Region Västerbotten — full company profile →

Who can join

18 and older, any sex, with Rectal Cancer or Lymph Node Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The combination of FDG-PET/CT and MRI at staging of rectal cancer in diagnosis is currently very little studied. The investigator have a unique opportunity to study this. Hypothetically, with PET/MR as one hybrid imaging method, alternatively as an additional method, it could increase the accuracy of rectal cancer of moderate and high risk type, especially at primary N-staging, but also in assessing other important prognostic factors such as T-staging, peritoneal involvement, metastasis to lateral lymph nodes, EMVI and MRF involvement. The same reasoning applies to the assessment of tumor regression after CRT. In the study, PET/MR is compared with PET/CT, diagnostic CT and MRI to evaluate the additional value of the hybrid imaging PET/MRI. The investigator also plan to evaluate how immunological, proliferative and prognostic biomarkers in blood and tumor tissue correlate with the radiological findings, and if the combination biomarker and radiology can provide additional prognostic information.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

PET/MRI and PET/CT hybrid imaging of rectal cancer - description and initial observations from the RECTOPET (REctal Cancer trial on PET/MRI/CT) study.
Rutegård MK, Båtsman M, Axelsson J, Brynolfsson P, et al · · 2019 · cited 25× · PMID 31337428 · DOI 10.1186/s40644-019-0237-1
Rectal cancer: a methodological approach to matching PET/MRI to histopathology.
Rutegård MK, Båtsman M, Blomqvist L, Rutegård M, et al · · 2020 · cited 10× · PMID 33129352 · DOI 10.1186/s40644-020-00347-6
Evaluation of MRI characterisation of histopathologically matched lymph nodes and other mesorectal nodal structures in rectal cancer.
Rutegård MK, Båtsman M, Blomqvist L, Rutegård M, et al · · 2025 · cited 6× · PMID 39838092 · DOI 10.1007/s00330-025-11361-2

Verify or expand the search:

Other recruiting trials for Rectal Cancer

Currently open trials in the same condition.

NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
NCT07501845 — Registry Maastro Applicator · recruiting
NCT07369531 — The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-pres · NA · recruiting
NCT07505472 — Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit · Phase 2, PHASE3 · recruiting

Other Region Västerbotten trials

Trials by the same sponsor.

NCT06330116 — Different Forms of OMT as Methods for Reducing Snoring and Mild to Moderate Sleep Apnea · NA · enrolling by invitation
NCT06717061 — Composed Abdominal Wall Analysis. Collecting Tissue and Blood From Patients Undergoing Elective Laparosopic Cholecystect · enrolling by invitation
NCT05604729 — The Effect on Envelope of Motion in Asymptomatic Bruxers · NA · unknown
NCT05353829 — Methotrexate in Patients with Early Rheumatoid Arthritis · Phase 4 · active not recruiting
NCT05309564 — Muscle Weakness Duration After Single Botulinum Toxin Injection in Masseter · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03846882 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Region Västerbotten
Last refreshed: 20 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03846882.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing